NK cell-based cancer immunotherapy: from basic biology to clinical development

Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright, Jennifer Wu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

59 Scopus citations


Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.

Original languageEnglish (US)
Article number7
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - Dec 2021


  • Cancer immunotherapy
  • Clinical trials
  • NK cell
  • iPSC

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research


Dive into the research topics of 'NK cell-based cancer immunotherapy: from basic biology to clinical development'. Together they form a unique fingerprint.

Cite this